Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
FreitasSMFrancoBSaragiottoGMoraisMASimabucoFMCunhaDTet al
They are now part of a broader medical discussion about obesity, insulin resistance, cardiovascular risk, fatty liver disease, inflammation, body composition, appetite signaling, and long-term metabolic health
Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options
Only a small fraction enters your bloodstream, limiting its systemic antioxidant effect
